IN-VITRO AND IN-VIVO STUDY OF SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM FOR HYPERTENSION
DOI:
https://doi.org/10.53555/bysn1g47Keywords:
Solid SMEDDS, in-vitro drug, pharmacokinetic studies, self-emulsification, microemulsionAbstract
Aim: The aim of the study was to formulate and evaluate self-micro emulsifying drug delivery system (SMEDDS) of nifedipine for hypertension.
Methodology: A series of formulations with different compositions were selected in the microemulsion region for assessment of self-emulsification time and droplet size. The optimized SMEDDS formulation was used for in vitro dissolution and pharmacokinetic studies in rats. The optimized formulation was further used for the preparation of various Solid SMEDDS(S-SMEDDS) formulations. formulations were evaluated for stability, robustness to dilution and self-emulsification efficiency. The in vitro release was almost similar for the S-SMEDDS as well liquid within 5 min.
Results: The optimized formulation had a particle size of 11.48nm, a transmittance of 98.2%, a zeta potential of -11.86 mV, and a polydispersibility index of 0.243. The solid SMEDDS tablet exhibited improved drug release (99.5% in 60 minutes) compared to the marketed tablet (67.09.75%) and pure drug (26.17%). This study demonstrates the potential of the SMEDDS approach to enhance the solubility and in-vitro drug release of drugs.
Conclusion: studies illustrated that adsorption to solid carrier technique could be a useful method to prepare the solid SMEDDS tablets from liquid SMEDDS, which can improve oral absorption of nifedipine, nearly equivalent to the liquid SMEDDS, but better in the formulation stability, drugs leakage and precipitation, etc.
References
1.Croft SL, Hogg J, Gutteridge WE, Hudson AT, Randall AW. (1992). The activity of hydroxynaphthoquinones against Liesh mania donovani. J Antimicrob Chemother, 30:827–32.
2.Vexenat JA, Croft SL, Campos JHF, Miles MA. (1998). Failure of Buparvaquone (Butalex) in the treatment of canine visceral leishmaniasis. Vet Parasitol, 77:71–3.
3.Mantyla A, Garnier T, Rautio J, Nevalainen T, Vepsalainen J, Koskinen A, et al. (2004). Synthesis, in vitro evaluation, and antileishmanial activity of water soluble prodrugs of buparva quone. J Med Chem, 47:188–95.
4.Hernandez-Trejo N, Kayser O, Steckel H, Muller RH. (2005). Characterization of nebulized buparvaquone nanosuspensions effect of nebulization technology. J Drug Target, 13:499–507.
5.Muller RH, Jacobs C. (2002). Buparvaquone mucoadhesive nanosuspension: Preparation, optimisation and long-term sta bility. Int J Pharm, 237:179–85.
6.Garnier T, Mantyla A, Jarvinen T, Lawrence J, Brown M, Croft S. (2007). In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother, 60:802–10.
7.Gursoy NR, Benita S. (2004). Self-emulsifying drug delivery sys tems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 58:173–82.
8. Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 29:278–87.
9.Patel AR, Vavia PR. (2007). Preparation and in vivo evaluation of SMEDDS (Self-Microemulsifying Drug Delivery System) con taining fenofibrate. AAPS J, 9:E344–52.
10.Porter CJH, Pouton CW, Cuine JF, Charman WN. (2008). Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug DelivRev, 60:673–91.
11.Grove M, Mullertz A, Nielsen LJ, Pederson PG. (2006). Bioavail ability of seocalcitol II: Development and characterisation of self-emulsifying drug delivery sysytems (SMEDDS) for oral administration containing medium and long chain triglycer ides. Eur J Pharm Sci, 28:233–42. 12.
12.Goddeeris C, Coacci J, Mooter GV. (2007). Correlation between digestion of the lipid phase of smedds and release of the anti HIV drug UC 781 and the anti-mycotic drug enilconazole from SMEDDS. Eur J Pharm Biopharm, 66:173–81.
13.Venkatesh G, Majid MIA, Ramanathan S, Mansor SM, Nair NK, Croft SL, et al. (2008). Optimization and validation of RP-HPLC UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: Application to phar macokinetic study. Biomed Chromatogr, 22:535–41.
14.Modi A, Tayade. P. (2007). A comparative solubility enhancement profile of valdecoxib with different solubilization approaches. Ind J Pharm Sci, 69:274–8.
15.Li P, Ghosh A, Wagner FG, Krill S, Joshi MY, Serajuddin TMA. (2005). Effect of combined use of nonionic surfactant on forma tion of oil-in-water microemulsions. Int J Pharm, 288:27–34.
16.Kommuru TR, Gurley B, Khan MA, Reddy IK. (2001). Self emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. Int J Pharm, 212(2):233–46.
17.Drug Development and Industrial Pharmacy Downloaded from informahealthcare.com by University of Guelph on 09/10/12 For personal use only.
18.Quan D., Xu G., Wu X. (2007). Studies on preparation and abso lute bioavailability of self emulsifying system containing puerarin. Chem Pharm Bull, 55:800–3.
19.Wei L, Sun P, Nie S, Pan W. (2005). Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm, 31:785–94.
20.Khoo SM, Humberstone AJ, Porter CJH, Edwards GA. (1998). Formulation and design and bioavailability assessment of lipidemic self-emulsifying formulations of halofantine. Int J Pharm, 167:155–64.
21.Pouton CW. (1997). Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev, 25:47–58.
22.Kinabo LD, Bogan JA. (1988). Parvaquone and buparvaquone: HPLC analysis and comparative pharmacokinetics in cattle. Acta Trop, 45(1):87–94.
23.Muraguri GR, Ngumi PN, Wesonga D, Ndungu SG, Wanjohi JM, Bang K, et al. (2006). Clinical efficacy and plasma concentrations of two formulations of buparvaquone in cattle infected with East Coast fever (Theileria parva infection). Res Vet Sci, 81(1):119 26.
24.Porter, C.J.H., A.M. Kaukonen, B.J. Boyd, G.A. Edwards, and W.N. Charman. 2004. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharmaceutical Research 21: 1405–1412.
25.Schulman, J.H., W. Stoekenius, and L.M.J. Prince. 1959. Mechanism of formation and structure of micro emulsions by electron microscopy. Journal of Physical Chemistry 63: 1677–1678.
26.Torrado, S., M.L. Lopez, G. Torrado, F. Bolas, S. Torrado, and R. Cadorniga. 1997. A novel formulation of albendazole solution: oral bioavailability and efficacy evaluation. Interna tional Journal of Pharmaceutics 156: 181–187.
